Financhill
Back

Blueprint Medicines Stock Price Chart

  • Based on the share price being above its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bullish and BPMC is experiencing slight buying pressure.

Blueprint Medicines Price Chart Indicators

Moving Averages Level Buy or Sell
8-day SMA: 129.46 Sell
20-day SMA: 129.04 Buy
50-day SMA: 122.45 Buy
200-day SMA: 100.81 Buy
8-day EMA: 129.4 Buy
20-day EMA: 128.51 Buy
50-day EMA: 121.79 Buy
200-day EMA: 104.98 Buy

Blueprint Medicines Technical Analysis Indicators

Chart Indicators Level Buy or Sell
MACD (12, 26): 1.8 Buy
Relative Strength Index (14 RSI): 76.66 Buy
Chaikin Money Flow: 0 -
Bollinger Bands Level Buy or Sell
Bollinger Bands (25): (128.32 - 129.44) Buy
Bollinger Bands (100): (87.11 - 124.89) Buy

Blueprint Medicines Technical Analysis

Technical Analysis: Buy or Sell?
8-day SMA:
20-day SMA:
50-day SMA:
200-day SMA:
8-day EMA:
20-day EMA:
50-day EMA:
200-day EMA:
MACD (12, 26):
Relative Strength Index (14 RSI):
Bollinger Bands (25):
Bollinger Bands (100):

Technical Analysis for Blueprint Medicines Stock

Is Blueprint Medicines Stock a Buy?

BPMC Technical Analysis vs Fundamental Analysis

Buy
55
Blueprint Medicines (BPMC) is a Buy

Is Blueprint Medicines a Buy or a Sell?

Blueprint Medicines Stock Info

Market Cap:
8.4B
Price in USD:
129.46
Share Volume:
0

Blueprint Medicines 52-Week Range

52-Week High:
129.65
52-Week Low:
73.04
Buy
55
Blueprint Medicines (BPMC) is a Buy

Blueprint Medicines Share Price Forecast

Is Blueprint Medicines Stock a Buy?

  • Blueprint Medicines share price is 129.46 while BPMC 8-day exponential moving average is 129.40, which is a Buy signal.
  • The stock price of BPMC is 129.46 while Blueprint Medicines 20-day EMA is 128.51, which makes it a Buy.
  • Blueprint Medicines 50-day exponential moving average is 121.79 while BPMC share price is 129.46, making it a Buy technically.
  • BPMC stock price is 129.46 and Blueprint Medicines 200-day simple moving average is 104.98, creating a Buy signal.

Fundamental Analysis of Blueprint Medicines

Is Blueprint Medicines a good investment?

  • Analysts estimate an earnings increase this quarter of $0.52 per share, an increase next quarter of $0.48 per share, an increase this year of $0.60 per share, and an increase next year of $1.50 per share.

Technical Analysis of Blueprint Medicines

Should I short Blueprint Medicines stock?

* Blueprint Medicines stock forecasts short-term for next days and weeks may differ from long term prediction for next month and year based on timeline differences.